ArticleMolecular therapy. Oncology2024
The reovirus variant RP116 is oncolytic in immunocompetent models and generates reduced neutralizing antibodies to Type 3 Dearing.
Ki-Hoon Song et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.